Stiff Person Syndrome is managed in a stepwise fashion. When the initial combination of GABA-enhancing antispasmodic agents fails to adequately control symptoms by 2–3 months, a structured next-line protocol addresses persistent focal and painful muscle spasms.

First-Line Treatment — Insufficient Response

The first line combines GABA-enhancing antispasmodic drugs — baclofen, gabapentin, and diazepam, with tizanidine and clonazepam as alternates — targeting reduced stiffness of the truncal and proximal limb muscles, reduced painful muscle spasms, and improved gait. When these goals are not met within 2–3 months, escalation to the next line is indicated.

Clinical Goal at This Stage

Reduction of focal and painful muscle spasms that persist despite first-line therapy.

Treatment Approach (Partial Overview)

This protocol adds adjunct antispasmodic agents — including a targeted option for focal spasms in selected patients — to address what first-line GABA-enhancing drugs did not fully control.

References

DOI: 10.1212/NXI.0000000000200109

Botulinum toxin: Only for focal spasms in selected patients
Botulinum toxin can be a useful agent for focal SPS providing significant relief in the injected areas.
Methocarbamol (Robaxin) at doses 1,000 mg QID can be helpful for painful spasms.
Dantrolene used for malignant hyperthermia binds to the ryanodine receptor and decreases intracellular calcium concentration blocking the release of calcium from the muscle sarcoplasmic reticulum.
It can potentially reduce stiffness, but it is rarely used.

View source ↗

Stiff Person Syndrome: Next Step When First-Line GABA-Enhancing Drugs Have Not Worked

First-Line Treatment — Insufficient Response

Clinical Goal at This Stage

Treatment Approach (Partial Overview)

References